<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992563</url>
  </required_header>
  <id_info>
    <org_study_id>C-09-023</org_study_id>
    <nct_id>NCT00992563</nct_id>
  </id_info>
  <brief_title>WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination</brief_title>
  <official_title>A Dose-Escalation Study of AL-39324 Suspension Versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and effects of
      investigational drug AL-39324 for the treatment of wet AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following a single administration, patients will be followed for 6 months postinjection.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of targeted adverse events occurring in the study eye</measure>
    <time_frame>Up to Day 7 after injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in central foveal thickness (CFT) at Month 1</measure>
    <time_frame>Baseline (Day 0), Month 1</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>AL-39324 Concentration Level A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-39324 ophthalmic suspension, single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-39324 Concentration Level B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-39324 ophthalmic suspension, single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-39324 Concentration Level C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-39324 ophthalmic suspension, single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-39324 Concentration Level D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-39324 ophthalmic suspension, single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AL-39324 Concentration Level E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL-39324 ophthalmic suspension, single intravitreal injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lucentis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranibizumab 10 mg/mL solution, single intravitreal injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL-39324 ophthalmic suspension</intervention_name>
    <arm_group_label>AL-39324 Concentration Level A</arm_group_label>
    <arm_group_label>AL-39324 Concentration Level B</arm_group_label>
    <arm_group_label>AL-39324 Concentration Level C</arm_group_label>
    <arm_group_label>AL-39324 Concentration Level D</arm_group_label>
    <arm_group_label>AL-39324 Concentration Level E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 10 mg/mL</intervention_name>
    <arm_group_label>Lucentis</arm_group_label>
    <other_name>Lucentis®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to give written informed consent, make the required study visits and follow
             instructions;

          -  The study eye:

               -  must have a primary diagnosis of choroidal neovascularization (CNV) secondary to
                  AMD;

               -  lesion must be no larger than 30 mm2;

               -  must have edema measuring greater than 340 μm;

               -  must have a visual score between 73 and 34 letters, inclusive;

               -  must be able to have clear picture taken of the back of the eye;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  The study eye must not have been treated for exudative AMD previously;

          -  The study eye must not have any other ocular disease, condition, infection, or recent
             surgery that would interfere with vision or examination of the back of the eye;

          -  The study eye must not have uncontrolled glaucoma;

          -  The study eye must not be missing a lens;

          -  Must not be taking any medication that is toxic to the lens;

          -  Must not be taking oral or ocular corticosteroids;

          -  Must not have an unstable or progressive condition that would interfere with study
             visits;

          -  Must not have allergies to any component of the test article or sensitivity to
             fluorescein dye;

          -  If female, must not be pregnant or nursing and must agree to adequate birth control;

          -  Must not be participating in another drug or device study within 30 days of screening
             for this study;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer M. Kissner, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <disposition_first_submitted>July 16, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 16, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 18, 2014</disposition_first_posted>
  <last_update_submitted>July 16, 2014</last_update_submitted>
  <last_update_submitted_qc>July 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wet age-related macular degeneration, exudative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

